Pfizer's $14 Billion Buy Signals That Cancer Drug Prices Will Remain High

Pfizer says it will purchase biotechnology upstart Medivation for $14 billion in cash. The main prize in the deal: Medivation’s prostate cancer drug, Xtandi, which costs $120,000 a year and generated $2.2 billion in sales over its last four quarters.

The deal also gets Pfizer a second, experimental drug for a rare form of breast cancer, talozaparib, that prevents cancer cells from repairing their DNA. A similar medicine from a small company called Tesaro recently succeeded in ovarian cancer, and, during the bidding process, Medivation chief executive David Hung has argued that the drug could be even bigger than Xtandi.

Back to news